Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, India.
Mini Rev Med Chem. 2021;21(14):1909-1924. doi: 10.2174/1389557521666210308143522.
Vanadium is considered to be biologically significant and several vanadium IV & V complexes have successfully been studied as chemotherapeutic agents like insulin mimetic, antibacterial, antioxidant, and anticancer activities. The divergent ligand systems also play a pivotal role in designing the metal complex with desired properties. Thus, the combination of both with their synergistic advantages results in a potential drug candidate. Different mechanistic pathways have been proposed to explain the antitumor effects of vanadium complexes, including induction of tyrosine residues phosphorylation, inhibition of key protein tyrosine phosphatases (PTPases), which in turn promote the activation of the extracellular regulated kinase cascading (ERK) pathway. In the current review, we have summarized the work on vanadium (V) complexes based on different ligand systems and their biological significance as an anticancer lead compound.
钒被认为具有重要的生物学意义，几种四价和五价的钒配合物已成功被研究为具有胰岛素模拟、抗菌、抗氧化和抗癌活性的化疗药物。不同的配体系统在设计具有所需性质的金属配合物方面也起着关键作用。因此，将两者结合起来并发挥其协同优势，就有可能成为一种潜在的候选药物。已经提出了不同的机制途径来解释钒配合物的抗肿瘤作用，包括诱导酪氨酸残基磷酸化，抑制关键的蛋白酪氨酸磷酸酶（PTPases），从而促进细胞外调节激酶级联（ERK）途径的激活。在本综述中，我们总结了基于不同配体系统的钒（V）配合物及其作为抗癌先导化合物的生物学意义方面的工作。
